PMID-32582207 – Cathelicidins Modulate TLR-Activation and Inflammation
Scheenstra MR, van Harten RM, Veldhuizen EJA, Haagsman HP, Coorens M. Cathelicidins modulate TLR-activation and inflammation. Front Immunol. 2020;11:1137.
Quick Reference
| Property | Value |
|---|---|
| PMID | 32582207 |
| DOI | 10.3389/fimmu.2020.01137 |
| Year | 2020 |
| Journal | Frontiers in Immunology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review of in vitro and in vivo studies) |
| Peptide(s) Studied | LL-37 |
Key Findings
- LL-37 (human cathelicidin) exhibits context-dependent dual immunomodulatory activity — it can both enhance and suppress TLR-mediated inflammatory responses
- In the presence of bacterial components (LPS, lipoteichoic acid), LL-37 can neutralize these ligands and suppress TLR4/TLR2 activation, reducing pro-inflammatory cytokine production
- Conversely, LL-37 can enhance TLR-mediated responses by facilitating nucleic acid delivery to endosomal TLR7/8/9, amplifying antiviral and type I interferon responses
- The pro- vs. anti-inflammatory outcome depends on ligand type, concentration, timing of exposure, and cellular context
- LL-37 interacts with multiple cell surface receptors beyond TLRs, including FPRL1/FPR2, P2X7, and EGFR, creating a complex immunomodulatory network
- Cathelicidins from different species share this dual modulatory capacity, suggesting it is a conserved evolutionary function
Study Design
Comprehensive narrative review synthesizing published in vitro studies, animal models, and mechanistic data on cathelicidin-TLR interactions. Covers human LL-37, mouse CRAMP, and cathelicidins from other species. Analyzes the structural basis for ligand binding and the downstream signaling consequences.
Limitations
- Narrative review rather than systematic review; potential for selection bias in cited studies
- Much of the mechanistic data derives from in vitro systems that may not fully reflect in vivo complexity
- Dose-dependent effects observed in vitro are difficult to extrapolate to physiological tissue concentrations
- Limited discussion of clinical translation or therapeutic implications
Clinical Relevance
This review is essential for understanding LL-37's nuanced immunomodulatory profile. For clinicians, the key insight is that LL-37 is not simply "anti-inflammatory" — its effects depend on the immunological context. In bacterial infection settings, LL-37 can neutralize endotoxin and reduce harmful inflammation. In viral contexts, it may enhance protective immune responses. This dual nature supports LL-37's therapeutic versatility but also underscores the importance of clinical context when considering its use for immune modulation, infection, or inflammatory conditions.
Related
#research #narrative-review #evidence-level-V